Yongliang Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yongliang Zhu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Rui Wang
Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
6 shared publicationsBin Yang
Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
4 shared publicationsSheng Yao
Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
4 shared publicationsTianhui Pan
Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
4 shared publicationsJingni Wu
Department of International Healthcare Center and General Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
3 shared publicationsShuyu Li
Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
3 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Taylor & Francis in ImmunoTargets and Therapy
- Vol. ume 15, 1-19
ANKRD22 Downregulation Reprograms Lipid Metabolism to Activate the Notch/Hes1 Pathway, Driving Immunosuppressive Macrophage Polarization in Colorectal Cancer
Background: Macrophages in colorectal cancer (CRC) are predominantly derived from monocytes, yet the mechanisms by which the tumor microenvironment (TME) regulates their differentiation dynamics and phenotypic commitment remains poorly defined. Although we previously identified ANKRD22 as a macrophage immunomodulator, the regulation of ANKRD22 by the TME and its temporal impact on monocyte‒macrophage differentiation are still unclear. Methods: We used untargeted metabolomics and cytokine microarrays to identify metabolites and cytokines from CRC cell supernatants that suppress ANKRD22 expression in macrophages. Immune infiltration in tumors was evaluated using cytometry by time-of-flight. The effects of ANKRD22 downregulation on monocyte-to-macrophage differentiation were investigated using scRNA-seq, scATAC-seq, and multiplex immunofluorescence staining. Results: CRC cell-derived metabolites and cytokines downregulated ANKRD22 expression in macrophages via the p38 MAPK/MAX pathway. Ankrd22-deficient macrophages accelerated subcutaneous tumor growth in mice, promoting the expansion of immunosuppressive CD206⁺CD163⁺ macrophage subsets and decreasing the number of CD8⁺CD44⁺CD62L− effector T cells. ANKRD22 downregulation delayed macrophage differentiation and maturation while increasing monocyte recruitment. Mechanistically, ANKRD22 suppression reduced the level of intracellular fatty acids, which in turn activated the Notch4/HES1 pathway, leading to differentiation arrest and immunosuppressive polarization. This process involved a newly identified early-differentiation immunosuppressive CD9⁺CD127⁺ macrophage subset within the TME. The combined pharmacological inhibition of Notch and long-acting IL-7 expression reversed these phenotypes, attenuated tumor growth, and diminished the CD9⁺CD127⁺ population. Conclusion: ANKRD22 downregulation reprograms fatty acid metabolism to activate the Notch4/HES1 pathway, promoting immunosuppressive macrophage polarization. ANKRD22 is a key regulator of macrophage plasticity and a promising therapeutic target for reprogramming the immunosuppressive TME in CRC.
- 1 November 2026
- Published by Taylor & Francis in ImmunoTargets and Therapy
- Vol. ume 15, 1-19
Open AccessANKRD22 Downregulation Reprograms Lipid Metabolism to Activate the Notch/Hes1 Pathway, Driving Immunosuppressive Macrophage Polarization in Colorectal Cancer
Background: Macrophages in colorectal cancer (CRC) are predominantly derived from monocytes, yet the mechanisms by which the tumor microenvironment (TME) regulates their differentiation dynamics and phenotypic commitment remains poorly defined. Although we previously identified ANKRD22 as a macrophage immunomodulator, the regulation of ANKRD22 by the TME and its temporal impact on monocyte‒macrophage differentiation are still unclear. Methods: We used untargeted metabolomics and cytokine microarrays to identify metabolites and cytokines from CRC cell supernatants that suppress ANKRD22 expression in macrophages. Immune infiltration in tumors was evaluated using cytometry by time-of-flight. The effects of ANKRD22 downregulation on monocyte-to-macrophage differentiation were investigated using scRNA-seq, scATAC-seq, and multiplex immunofluorescence staining. Results: CRC cell-derived metabolites and cytokines downregulated ANKRD22 expression in macrophages via the p38 MAPK/MAX pathway. Ankrd22-deficient macrophages accelerated subcutaneous tumor growth in mice, promoting the expansion of immunosuppressive CD206⁺CD163⁺ macrophage subsets and decreasing the number of CD8⁺CD44⁺CD62L− effector T cells. ANKRD22 downregulation delayed macrophage differentiation and maturation while increasing monocyte recruitment. Mechanistically, ANKRD22 suppression reduced the level of intracellular fatty acids, which in turn activated the Notch4/HES1 pathway, leading to differentiation arrest and immunosuppressive polarization. This process involved a newly identified early-differentiation immunosuppressive CD9⁺CD127⁺ macrophage subset within the TME. The combined pharmacological inhibition of Notch and long-acting IL-7 expression reversed these phenotypes, attenuated tumor growth, and diminished the CD9⁺CD127⁺ population. Conclusion: ANKRD22 downregulation reprograms fatty acid metabolism to activate the Notch4/HES1 pathway, promoting immunosuppressive macrophage polarization. ANKRD22 is a key regulator of macrophage plasticity and a promising therapeutic target for reprogramming the immunosuppressive TME in CRC.
- Open Access
- 24 February 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (3) , 101981
An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α1/2 shedding
- 24 February 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (3) , 101981
Open AccessAn epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α1/2 shedding
- Open Access
- 1 February 2025
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 74 (3) , 1-14
ANKRD22 participates in the proinflammatory activities of macrophages in the colon cancer tumor microenvironment
Tumor-associated macrophages (TAMs) are among the most common types of immune cells in the colon cancer microenvironment. Reprogramming M2-type TAMs with immunosuppressive functions into M1-type TAMs with proinflammatory functions is a novel strategy for reshaping the tumor microenvironment (TME) and enhancing the efficacy of immunotherapy in colon cancer. However, the key molecules and mechanisms underlying TAM polarization require further clarification. Our previous study suggested that ANKRD22 may play a role in regulating the functional state transition of macrophages. However, the expression levels of ANKRD22 in colon TAMs and its specific effects on tumor proliferation remain unclear. In the present study, we observed elevated ANKRD22 expression in M1-type TAMs. The expression level of ANKRD22 was positively correlated with the survival period of patients with colon cancer and with the infiltration abundance of M1-type TAMs, and ANKRD22 expression was negatively correlated with the infiltration abundance of M2-type TAMs. A significant decrease in ANKRD22 expression in macrophages cocultured with colon cancer cell culture supernatant as well as in macrophages directly derived from colorectal cancer tissues was observed. Single-cell RNA sequencing, spatial transcriptomic studies, and subcutaneous xenograft experiments in mice revealed that Ankrd22 silencing altered the subtype distribution of macrophages, attenuated their proinflammatory activity, and enhanced their protumor activity. Additionally, we identified a small-molecule ANKRD22 upregulator that could aid in the development of novel therapeutics targeting TAM remodeling.
- 1 February 2025
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 74 (3) , 1-14
Open AccessANKRD22 participates in the proinflammatory activities of macrophages in the colon cancer tumor microenvironment
Tumor-associated macrophages (TAMs) are among the most common types of immune cells in the colon cancer microenvironment. Reprogramming M2-type TAMs with immunosuppressive functions into M1-type TAMs with proinflammatory functions is a novel strategy for reshaping the tumor microenvironment (TME) and enhancing the efficacy of immunotherapy in colon cancer. However, the key molecules and mechanisms underlying TAM polarization require further clarification. Our previous study suggested that ANKRD22 may play a role in regulating the functional state transition of macrophages. However, the expression levels of ANKRD22 in colon TAMs and its specific effects on tumor proliferation remain unclear. In the present study, we observed elevated ANKRD22 expression in M1-type TAMs. The expression level of ANKRD22 was positively correlated with the survival period of patients with colon cancer and with the infiltration abundance of M1-type TAMs, and ANKRD22 expression was negatively correlated with the infiltration abundance of M2-type TAMs. A significant decrease in ANKRD22 expression in macrophages cocultured with colon cancer cell culture supernatant as well as in macrophages directly derived from colorectal cancer tissues was observed. Single-cell RNA sequencing, spatial transcriptomic studies, and subcutaneous xenograft experiments in mice revealed that Ankrd22 silencing altered the subtype distribution of macrophages, attenuated their proinflammatory activity, and enhanced their protumor activity. Additionally, we identified a small-molecule ANKRD22 upregulator that could aid in the development of novel therapeutics targeting TAM remodeling.
- Open Access
- 31 December 2024
- Published by Elsevier in Ageing Research Reviews
- Vol. 104, 102653
The immunosenescence clock: A new method for evaluating biological age and predicting mortality risk
- 31 December 2024
- Published by Elsevier in Ageing Research Reviews
- Vol. 104, 102653
Open AccessThe immunosenescence clock: A new method for evaluating biological age and predicting mortality risk
- Open Access
- 12 June 2024
- Published by Elsevier in Life Sciences
- Vol. 351, 122802
Exploring the multifaceted role of adenosine nucleotide translocase 2 in cellular and disease processes: A comprehensive review
- 12 June 2024
- Published by Elsevier in Life Sciences
- Vol. 351, 122802
Open AccessExploring the multifaceted role of adenosine nucleotide translocase 2 in cellular and disease processes: A comprehensive review
- Open Access
- 23 February 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (2) , e005527
ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer
Background: Ovarian cancer is the deadliest type of malignant gynecological tumor. Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are involved ovarian cancer and are closely related to adverse outcomes. However, the immunosuppressive mechanism of PMN-MDSCs remains elusive. Methods: The types and numbers of ANKRD22-expressing cells were investigated by bioinformatics analysis and immunohistochemical staining. Ankrd22-/- C57BL/6 mice were constructed with CRISPR-Cas9 technology. Mouse PMN-MDSCs were obtained from bone marrow (BM)-derived CD11b+Ly6G+Ly6Clow cells sorted by fluorescence-activated cell sorting with treatment of GM-CSF and IL-6, and the immunosuppressive activity of PMN-MDSCs was evaluated by flow cytometry (FCM) and ELISA. The expression level of CCR2 and the exogenous glucose uptake capacity were determined by FCM. RT-qPCR was used to detect ANKRD22 expression in CD11b+HLA-DR-CD14-CD15+ cells from human ovarian cancer tissues, and the correlations of ANKRD22 expression with the clinical characteristics and prognosis of patients were evaluated by the χ2 test. Results: We identified a novel protein involved in regulating the immunosuppressive ability of PMN-MDSCs, ANKRD22. Ankrd22 expression was high in mouse CD11b+Ly6G+Ly6Clow cells and could be significantly downregulated after exposure to a simulated microenvironmental stimulus. Knockout of Ankrd22 increased the expression level of CCR2 of CD11b+Ly6G+Ly6Clow cells and the immunosuppressive activity of PMN-MDSCs. BM-derived CD11b+Ly6G+Ly6Clow cells of Ankrd22-/- mice significantly promoted the proliferation of ovarian cancer cells in tumor xenograft mouse models. Mechanistically, RNA sequencing showed that Wdfy1 expression was obviously increased in Ankrd22-knockout BM-derived CD11b+Ly6G+ Ly6Clow cells and that ectopic expression of Wdfy1 increased the levels of Arg1, Inos, Ido and Pdl1 in Ankrd22+/+ PMN-MDSCs derived from BM-derived CD11b+Ly6G+Ly6Clow cells. Surprisingly, an ANKRD22-activating candidate small-molecule compound attenuated the immunosuppressive activity of Ankrd22+/+ PMN-MDSCs. Finally, we found that low ANKRD22 levels in CD11b+HLA-DR-CD14-CD15+ cells derived from primary ovarian tissues were associated with a more advanced International Federation of Gynecology and Obstetrics stage, a higher recurrence rate, and a higher neutrophil-to-lymphocyte ratio. Conclusions: These results suggest that ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs.
- 23 February 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (2) , e005527
Open AccessANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer
Background: Ovarian cancer is the deadliest type of malignant gynecological tumor. Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are involved ovarian cancer and are closely related to adverse outcomes. However, the immunosuppressive mechanism of PMN-MDSCs remains elusive. Methods: The types and numbers of ANKRD22-expressing cells were investigated by bioinformatics analysis and immunohistochemical staining. Ankrd22-/- C57BL/6 mice were constructed with CRISPR-Cas9 technology. Mouse PMN-MDSCs were obtained from bone marrow (BM)-derived CD11b+Ly6G+Ly6Clow cells sorted by fluorescence-activated cell sorting with treatment of GM-CSF and IL-6, and the immunosuppressive activity of PMN-MDSCs was evaluated by flow cytometry (FCM) and ELISA. The expression level of CCR2 and the exogenous glucose uptake capacity were determined by FCM. RT-qPCR was used to detect ANKRD22 expression in CD11b+HLA-DR-CD14-CD15+ cells from human ovarian cancer tissues, and the correlations of ANKRD22 expression with the clinical characteristics and prognosis of patients were evaluated by the χ2 test. Results: We identified a novel protein involved in regulating the immunosuppressive ability of PMN-MDSCs, ANKRD22. Ankrd22 expression was high in mouse CD11b+Ly6G+Ly6Clow cells and could be significantly downregulated after exposure to a simulated microenvironmental stimulus. Knockout of Ankrd22 increased the expression level of CCR2 of CD11b+Ly6G+Ly6Clow cells and the immunosuppressive activity of PMN-MDSCs. BM-derived CD11b+Ly6G+Ly6Clow cells of Ankrd22-/- mice significantly promoted the proliferation of ovarian cancer cells in tumor xenograft mouse models. Mechanistically, RNA sequencing showed that Wdfy1 expression was obviously increased in Ankrd22-knockout BM-derived CD11b+Ly6G+ Ly6Clow cells and that ectopic expression of Wdfy1 increased the levels of Arg1, Inos, Ido and Pdl1 in Ankrd22+/+ PMN-MDSCs derived from BM-derived CD11b+Ly6G+Ly6Clow cells. Surprisingly, an ANKRD22-activating candidate small-molecule compound attenuated the immunosuppressive activity of Ankrd22+/+ PMN-MDSCs. Finally, we found that low ANKRD22 levels in CD11b+HLA-DR-CD14-CD15+ cells derived from primary ovarian tissues were associated with a more advanced International Federation of Gynecology and Obstetrics stage, a higher recurrence rate, and a higher neutrophil-to-lymphocyte ratio. Conclusions: These results suggest that ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs.
- Open Access
- 17 January 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 147, 112649
ANKRD22 is a novel therapeutic target for gastric mucosal injury
- 17 January 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 147, 112649
Open AccessANKRD22 is a novel therapeutic target for gastric mucosal injury
- Open Access
- 3 September 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-19
Circulating MiR-1290 as a potential diagnostic and disease monitoring biomarker of human gastrointestinal tumors
Background: Gastrointestinal tumors are a leading cause of mortality worldwide. As shown in our previous study, miR-1290 is overexpressed in colorectal cancer (CRC) and promotes tumor progression. We therefore aimed to explore the potential of circulating miR-1290 as a biomarker for gastrointestinal cancer. Methods: A serum miRNA sequencing analysis was performed. Then, circulating miRNA detection technologies were established. The expression of miR-1290 was analyzed in gastrointestinal tumor cell lines and culture supernatants. Expression levels of circulating miR-1290 in clinical samples were examined. Associations between miR-1290 expression and clinicopathologic characteristics were analyzed. Xenograft models were generated to assess the fluctuation in serum miR-1290 levels during disease progression. Results: Through miRNA sequencing, we identified that miR-1290 was overexpressed in serum samples from patients with CRC. We confirmed that human gastrointestinal tumor cells express and secrete miR-1290. The circulating miR-1290 levels was up-regulated in patients with pancreatic cancer (PC) (p < 0.01), CRC (p < 0.05), and gastric cancer (GC) (p < 0.01). High miR-1290 expression levels were associated with tumor size, lymphatic invasion, vascular invasion, distant metastasis, tumor differentiation and AJCC stage in patients with PC and CRC. The area under the curve (AUC) was 0.8857 in patients with PC, with 60.9% sensitivity and 90.0% specificity. The AUC was 0.7852 in patients with CRC, with 42.0% sensitivity and 90.0% specificity. In patients with GC, the AUC was 0.6576, with 26.0% sensitivity and 90.0% specificity. The in vivo model verified that the circulating miR-1290 level was significantly increased after tumor formation and decreased after drug treatment. Conclusions: Our findings indicate that circulating miR-1290 is a potential biomarker for gastrointestinal cancer diagnosis and monitoring.
- 3 September 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-19
Open AccessCirculating MiR-1290 as a potential diagnostic and disease monitoring biomarker of human gastrointestinal tumors
Background: Gastrointestinal tumors are a leading cause of mortality worldwide. As shown in our previous study, miR-1290 is overexpressed in colorectal cancer (CRC) and promotes tumor progression. We therefore aimed to explore the potential of circulating miR-1290 as a biomarker for gastrointestinal cancer. Methods: A serum miRNA sequencing analysis was performed. Then, circulating miRNA detection technologies were established. The expression of miR-1290 was analyzed in gastrointestinal tumor cell lines and culture supernatants. Expression levels of circulating miR-1290 in clinical samples were examined. Associations between miR-1290 expression and clinicopathologic characteristics were analyzed. Xenograft models were generated to assess the fluctuation in serum miR-1290 levels during disease progression. Results: Through miRNA sequencing, we identified that miR-1290 was overexpressed in serum samples from patients with CRC. We confirmed that human gastrointestinal tumor cells express and secrete miR-1290. The circulating miR-1290 levels was up-regulated in patients with pancreatic cancer (PC) (p < 0.01), CRC (p < 0.05), and gastric cancer (GC) (p < 0.01). High miR-1290 expression levels were associated with tumor size, lymphatic invasion, vascular invasion, distant metastasis, tumor differentiation and AJCC stage in patients with PC and CRC. The area under the curve (AUC) was 0.8857 in patients with PC, with 60.9% sensitivity and 90.0% specificity. The AUC was 0.7852 in patients with CRC, with 42.0% sensitivity and 90.0% specificity. In patients with GC, the AUC was 0.6576, with 26.0% sensitivity and 90.0% specificity. The in vivo model verified that the circulating miR-1290 level was significantly increased after tumor formation and decreased after drug treatment. Conclusions: Our findings indicate that circulating miR-1290 is a potential biomarker for gastrointestinal cancer diagnosis and monitoring.
- Open Access
- 1 January 2021
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 12 (4) , 1433-1455
ANKRD22 Drives Rapid Proliferation of Lgr5+ Cells and Acts as a Promising Therapeutic Target in Gastric Mucosal Injury
- 1 January 2021
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 12 (4) , 1433-1455
Open AccessANKRD22 Drives Rapid Proliferation of Lgr5+ Cells and Acts as a Promising Therapeutic Target in Gastric Mucosal Injury
- Open Access
- 1 January 2020
- Published by Ivyspring International Publisher in Theranostics
- Vol. 10 (2) , 516-536
ANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells
Background: The leading cause of poor prognosis in colorectal cancer (CRC) is the presence of colorectal cancer-initiating cells (CCICs). The interplay between the tumor microenvironment (TME) and CRC cells induces reacquisition of initiating cell characteristics, but the underlying mechanisms remain elusive.
- 1 January 2020
- Published by Ivyspring International Publisher in Theranostics
- Vol. 10 (2) , 516-536
Open AccessANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells
Background: The leading cause of poor prognosis in colorectal cancer (CRC) is the presence of colorectal cancer-initiating cells (CCICs). The interplay between the tumor microenvironment (TME) and CRC cells induces reacquisition of initiating cell characteristics, but the underlying mechanisms remain elusive.